According to the brokerage, India core US businesses and generic Gleevec launch are critical to drive its FY17 EBITDA (earnings before interest, tax, depreciation and amortisation). It expects 40 percent Y-o-Y FY17 EBITDA growth for Sun Pharma.
| Subscribe To Our Free Newsletter |
